肺淋巴上皮瘤样癌诊断与治疗研究进展  

The Clinical Diagnosis and Treatment of Pulmonary Lymphoepithelial-like Carcinoma:a Mini-review

作　　者：王奕婷[1] 黄永青 王倩[1] 李勇[1] 张凌[1] WANG Yi-ting;HUANG Yong-qing;WANG Qian;LI Yong;ZHANG Ling(Department of Oncology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第一附属医院肿瘤科,南昌330006

出　　处：《实用临床医学（江西）》2024年第3期126-132,共7页Practical Clinical Medicine

摘　　要：肺淋巴上皮瘤样癌是一种罕见的原发性肺癌,与Epstein-Barr病毒(Epstein-Barr virus,EBV)感染密切相关,好发于亚裔、年轻、不吸烟人群。肺癌常见的驱动基因在肺淋巴上皮瘤样癌中发生率低,程序性死亡受体配体1(programmed death ligand 1,PD-L1)表达多为阳性。肺淋巴上皮瘤样癌多采取以手术为主的综合治疗模式,含铂类的双药化疗是目前晚期肺淋巴上皮瘤样癌最常见的一线化疗方案,随着肿瘤的诊断与治疗进入精准时代,靶向治疗、免疫治疗可能成为肺淋巴上皮瘤样癌治疗新的突破口。文章综述了肺淋巴上皮瘤样癌最新的诊断与治疗进展,以期为临床医师及研究学者提供参考。Pulmonary lymphoepithelioma-like carcinoma is a rare primary lung cancer that is strongly associated with Epstein-Barr virus(EBV)infection and is prevalent in Asian young nonsmoking populations.Common driver genes in lung cancer have a low prevalence in pulmonary lymphoepithelioma-like carcinoma,and the expression of programmed death receptor ligand 1(PD-L1)is mostly positive.Pulmonary lymphoepithelioma-like carcinoma is mostly treated with a surgical-based comprehensive modality,and platinum-containing dual drug chemotherapy is currently the most common first-line chemotherapy regimen for advanced pulmonary lymphoepithelial-like carcinoma.In the era of precision treatment,targeted therapy and immunotherapy may become new breakthroughs in the management of the disease.This article reviews the latest diagnostic and therapeutic advances in pulmonary lymphoepithelioma-like carcinoma,with the aim of providing reference for clinicians and researchers.

关 键 词：肺淋巴上皮瘤样癌 EPSTEIN-BARR病毒 程序性死亡受体配体1 免疫治疗 肿瘤微环境 诊断 治疗 

分 类 号：R734.2[医药卫生—肿瘤]